GLG News by Experts on Pay-for-Performance Plans

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Erythropoiesis Stimulating Agents could be further restricted by Payers (Medicare, PBMs, and Healthplans)

January 28, 2008

Analysis of:FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov

Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents.   Restrictions will come in the form of prior authorizations and other utilization management techniques.

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it

October 29, 2007

Analysis of:Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com

Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems.  Their biggest issue that brought failure was the lack of payer coverage.  Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin at the price being commanded by Pfizer.

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

WalMart Expansion of $4 generics

October 3, 2007

Analysis of:Wal-Mart Expands Offerings Of $4 Generic Drugs | online.wsj.com

WalMarts strategy on expanding $4 generics is not at a loss.  They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit. 

Dea BelaziPharmacy ConsultantDea Belazi, PharmD, MPH, PAHM

Indian Pharmaceutical Manufacturers

October 3, 2007

Analysis of:Drug discovery hits India | www.icis.com

Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.

Page : 11 to 4 of 4